U.S. Markets closed

RegeneRx Biopharmaceuticals, Inc. (RGRX)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.28450.00 (0.00%)
At close: 2:17PM EDT
People also watch
LCARPRTXAOLSSNGXPHLI
Interactive chart
Previous Close0.2845
Open0.2845
Bid0.0000 x
Ask0.0000 x
Day's Range0.2800 - 0.2845
52 Week Range0.2500 - 0.5800
Volume11,115
Avg. Volume21,120
Market Cap30.41M
Beta1.88
PE Ratio (TTM)142.25
EPS (TTM)0
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
    Capital Cube3 days ago

    RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017

    Categories: Yahoo FinanceGet free summary analysis RegeneRx Biopharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of RegeneRx Biopharmaceuticals, Inc. – MediWound Ltd., XOMA Corporation, Novartis AG Sponsored ADR, Sevion Therapeutics, Inc., Akorn, Inc., Johnson & Johnson, Rigel Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc. Class A, ... Read more (Read more...)

  • PR Newswire20 days ago

    RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017

    As previously reported, the double-masked, placebo-controlled trial in 317 patients with dry eye syndrome demonstrated that after 28 days of treatment, RGN-259 was safe and significantly reduced ocular discomfort both during and after exposure to a controlled adverse environment (CAE®).  Ocular discomfort is a symptom of dry eye syndrome.  ReGenTree also reported that after 28 days of treatment RGN-259 significantly reduced total and inferior corneal fluorescein staining in a subgroup of subjects with compromised baseline tear film break-up time, which is a sign of dry eye syndrome.  Both symptom and sign improvements are typically required by FDA to obtain marketing approval of a pharmaceutical treatment for dry eye. A second Phase 3 dry eye trial (ARISE-2) designed to reproduce the results seen in ARISE-1 is currently underway in the U.S. with over 500 patients.  The trial is expected to be completed by the fall of 2017.

  • RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
    Capital Cube2 months ago

    RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017

    Categories: Yahoo Finance Get free summary analysis RegeneRx Biopharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of RegeneRx Biopharmaceuticals, Inc. – MediWound Ltd., XOMA Corporation, Sevion Therapeutics, Inc., Akorn, Inc., Rigel Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc. Class A, Mateon Therapeutics, Inc. and Capstone Therapeutics Corp. ... Read more (Read more...)